Ticagrelor or prasugrel in patients with acute coronary syndromes - New England Journal of Medicine - 2019

Brief Summary:

In patients with acute coronary syndrome (ACS), for whom an invasive evaluation is planned, prasugrel was associated with a 2.4% absolute reduction in the primary outcome of death, nonfatal MI, and stroke, driven primarily by reduction in nonfatal myocardial infarction (although there was also numerically lower all-cause mortality). Stent thrombosis was rare in both groups, but numerically lower with prasugrel. Major bleeding rates were similar in both groups.